Corneal Neovascularization Treatment: How It Works, Results and What to Expect

Corneal neovascularization treatment aims to control the inflammation, oxygen shortage, infection, or surface injury that has caused abnormal blood vessels to grow into the normally clear cornea. Early ophthalmology assessment can help protect corneal clarity and vision, while treatment and recovery depend on the cause and extent of vessel growth.

Overview: How corneal neovascularization treatment works

Corneal neovascularization treatment works by stopping the trigger that is encouraging new blood vessels to grow into the cornea, the transparent window at the front of the eye. Depending on the cause, an ophthalmologist may recommend lubricating treatment, anti-inflammatory or antimicrobial medicines, changes to contact lens wear, treatment for eyelid or tear-film problems, or a procedure to close persistent vessels. The plan is individual because the best approach depends on whether the vessels are new and active, how far they extend into the cornea, and whether vision is affected.

The cornea normally has no blood vessels. When it is repeatedly irritated, inflamed, deprived of oxygen, infected, or injured, the body may form vessels to support healing. Although this response can be protective at first, vessels may reduce corneal clarity, promote scarring, and complicate future corneal surgery or transplantation if they progress.

Some cases are mild and found during a routine eye examination. Others require timely care because they are associated with pain, sensitivity to light, redness, discharge, or visual changes. A specialist will address both the visible vessels and the condition responsible for them, rather than treating the vessels alone.

Symptoms, causes and risk factors

Corneal neovascularization itself may not cause symptoms in its early stages. Symptoms often come from the underlying corneal or ocular-surface problem and can include persistent eye redness, irritation, a gritty sensation, watering, light sensitivity, blurred vision, or discomfort when wearing contact lenses. Advanced vessel growth or associated scarring can affect sight if it reaches the central cornea.

Long-term or overnight contact lens wear is a common preventable contributor, particularly when lenses fit poorly, are not replaced as advised, or are worn while sleeping. These situations may reduce oxygen reaching the cornea. Other possible causes include dry eye disease, eyelid inflammation, allergic eye disease, chemical or thermal injury, trauma, previous eye surgery, chronic inflammation, and corneal infections.

Risk is also higher when the corneal surface does not heal normally. Conditions involving reduced tear production, abnormal eyelid closure, autoimmune inflammation, or repeated infection may damage the surface over time. People should not assume that redness in a contact lens-wearing eye is minor, since infection and corneal inflammation need prompt assessment.

How serious is corneal neovascularization?

Corneal neovascularization can be mild, but it should be assessed because it may signal ongoing damage to the cornea. Small, superficial vessels near the edge of the cornea may remain stable when the underlying cause is corrected. More extensive, deeper, or centrally located vessels have a greater potential to interfere with transparency and vision.

The condition can also matter when a person may need corneal transplantation in the future. Blood vessels can increase immune activity in the cornea and may raise the chance of transplant rejection. For this reason, ophthalmologists aim to reduce active inflammation and vessel growth before considering a graft where possible.

Urgency depends on accompanying symptoms and the suspected cause. Sudden vision change, significant pain, increasing redness, discharge, injury, or contact lens-related discomfort warrants urgent eye assessment. With early, cause-directed treatment, many people can limit progression and preserve good visual function.

What are the stages of corneal neovascularization?

There is no single universal staging system used in every clinic. In practice, ophthalmologists describe corneal neovascularization by its activity, depth, location, and extent. Early disease often consists of fine superficial vessels growing inward from the limbus, the border between the cornea and the white of the eye.

As the process progresses, vessels may extend farther toward the centre of the cornea and become more numerous. Active vessels can appear bright red and may be accompanied by inflammation. Older vessels may become pale or “ghost” vessels after blood flow decreases; however, the channels can sometimes reopen if irritation or inflammation returns.

More advanced disease may involve deeper vessels, scarring, lipid deposits around leaky vessels, or central corneal involvement. These findings guide treatment decisions and help the clinician monitor whether treatment is controlling the disease over time.

What is the grading scale for corneal neovascularization?

Corneal neovascularization grading is not fully standardised across all eye clinics and research studies. A common clinical approach records how many millimetres vessels extend from the limbus into the cornea, often alongside the number of corneal quadrants involved. This creates a useful baseline for comparing future examinations.

Some systems use grades such as mild, moderate, or severe according to vessel depth and distance from the corneal edge. Others document superficial versus deep vessels, the degree of redness or activity, and whether vessels approach or cross the central visual axis. Photographs and slit-lamp examination can make follow-up more accurate.

A grade does not predict vision by itself. A small area of vessels near the centre may be more important for sight than a larger area near the edge. The ophthalmologist interprets grading together with corneal clarity, scarring, symptoms, and the underlying diagnosis.

Candidacy and step-by-step treatment options

Anyone with confirmed corneal neovascularization may benefit from ophthalmology review, but the treatment intensity differs by cause and severity. The eye specialist will ask about contact lens habits, prior eye injury or surgery, symptoms, general health conditions, and current medicines. Examination usually includes visual acuity testing, slit-lamp microscopy, assessment of the tear film and eyelids, and fluorescein dye to identify surface damage; further tests may be needed if infection or autoimmune disease is suspected.

Step one is to remove or control the trigger. This may mean temporarily stopping contact lens use, replacing unsuitable lenses, improving lens hygiene, treating dry eye or eyelid disease, or managing infection. Prescription anti-inflammatory eye drops may be appropriate in selected non-infectious cases, but they must be used only under supervision because they can worsen or mask certain infections. Antimicrobial treatment is used when infection is diagnosed or strongly suspected.

For persistent or vision-threatening vessels, specialists may consider therapies that target abnormal vessel activity, such as carefully selected anti-vascular endothelial growth factor treatment, laser or fine-needle diathermy to occlude vessels, or surface reconstruction in complex ocular-surface disease. These options are not suitable for every person and may be combined with treatment of the underlying condition. If significant irreversible scarring remains, corneal transplantation may be considered for carefully selected patients after inflammation and vascular activity have been addressed.

At Acibadem International, multidisciplinary eye-care specialists in JCI-accredited hospitals can assess corneal conditions and discuss appropriate diagnostic and treatment pathways for international patients.

Benefits, risks and recovery timeline

The main potential benefit of treatment is to stop progression, settle inflammation, relieve symptoms from the underlying surface disease, and preserve corneal clarity. In some cases, newer active vessels become less prominent once the cause is controlled. Treatment cannot always remove established vessels or reverse existing scarring, which is why early assessment is valuable.

How long does it take for corneal neovascularization to heal? Surface irritation or active inflammation may improve over days to weeks once the trigger is treated, while visible vessel regression often takes weeks to months. Chronic vessels may become inactive rather than disappear completely. Follow-up intervals vary, but regular review is important until the eye is stable.

Risks depend on the treatment used. Medicated drops may cause temporary stinging, blurred vision after instillation, allergy, or other side effects; steroid drops require monitoring for pressure changes, cataract risk, and unrecognised infection. Procedures can cause temporary redness, discomfort, inflammation, or recurrence of vessels, and occasionally need repeat treatment. The treating ophthalmologist will explain expected benefits, alternatives, and procedure-specific risks before care begins.

Prevention, self-care and when to seek medical care

Prevention focuses on protecting the corneal surface. Contact lens wearers should follow their clinician’s instructions for wear time, cleaning, replacement, and follow-up, and should not sleep in lenses unless specifically prescribed. Lenses should be removed if the eye becomes red, painful, light-sensitive, or blurry, and should not be worn while waiting for urgent assessment. Using only recommended lens solutions and avoiding tap water exposure can also reduce infection risk.

People with dry eye, allergies, or eyelid inflammation should follow their clinician’s plan to keep the ocular surface stable. They should avoid rubbing the eyes and should not use leftover antibiotic or steroid drops without medical advice. General lubricating drops may help some people, but a clinician should guide their use when symptoms are persistent or when a corneal condition is known.

When to seek medical care: an urgent eye assessment is needed for reduced vision, moderate or severe pain, marked light sensitivity, new discharge, an eye injury, a chemical splash, or a red eye in a contact lens wearer. A routine but timely ophthalmology appointment is appropriate for ongoing redness, recurrent discomfort, worsening contact lens tolerance, or blurred vision that does not settle. Prompt care helps identify infections and other treatable causes before complications develop.

Frequently asked questions

Can corneal neovascularization go away on its own?

It may improve when the underlying irritation or lack of oxygen is corrected, particularly when vessels are new and superficial. However, established vessels may remain as inactive channels or leave scarring. An ophthalmologist can determine whether observation or active treatment is appropriate.

Can contact lenses cause corneal neovascularization?

Yes. Long wear times, sleeping in lenses, poor lens fit, and reduced oxygen transmission can contribute to corneal vessel growth. Contact lens wear should usually be paused if there is redness, pain, light sensitivity, or reduced vision until an eye professional has assessed the eye.

Is corneal neovascularization painful?

The blood vessels themselves may not be painful. Pain often reflects the associated cause, such as dry eye disease, inflammation, a corneal abrasion, or infection. Painful red eyes, especially in contact lens wearers, need prompt medical review.

Can eye drops remove corneal blood vessels?

Eye drops mainly treat the inflammation, dryness, infection, or other trigger that is driving vessel growth. They may help newer vessels become less active, but they do not reliably eliminate established vessels. Some people with persistent vessels may be considered for specialist procedures.

Does corneal neovascularization cause blindness?

Most cases do not lead to blindness, particularly when the cause is identified and controlled early. Extensive vessels, scarring, infection, or involvement of the central cornea can reduce vision and require specialist care. New or worsening visual loss should be assessed urgently.

Will corneal neovascularization return after treatment?

It can return if the underlying problem persists or recurs, such as ongoing contact lens-related oxygen deprivation, chronic inflammation, or severe dry eye. Continuing preventive measures and attending follow-up appointments can reduce the likelihood of recurrence. The long-term outlook depends on the cause and the health of the corneal surface.

References

• American Academy of Ophthalmology
• National Eye Institute
• Merck Manual Professional Edition
• Royal College of Ophthalmologists

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.